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CORRESPONDENCE
Figure 1. A, Slowly replicating lymphocytic choriomeningitis virus (LCMV; or, in analogy, respiratory syncytial virus [RSV]) spreads to lymphoid
organs (e.g., spleen), inducing strong cytotoxic T cell (CTL) responses. CTL then cause severe immunopathologic disease in the brain (or lung
for RSV). B, Antiviral antibodies prevent viral hematogenic spread of the slowly replicating LCMV isolate and, therefore, CTL induction almost
completely. After this, no immunopathologic disease develops. However, because of subtotal lack of CTL, antiviral antibodies also inhibit fast
virus elimination in the brain. C, Despite antiviral antibodies, faster replicating LCMV isolates (or possibly RSV) induce cellular immune responses
and cause immunopathologic disease. In the latter (C), the time factor is crucial; although neutralizing antibodies reduce hematogenic spread,
this is not sufficient to abrogate CTL induction and immunopathology completely. Moreover, because antigenic stimulation in lymphoid organs
is reduced, efficient CTL responses occur only some days later, enabling more virus spread in primary organs, unfavorable CTL virus kinetics,
and immunopathologic disease. Hexagons, viruses; squares, CTL; shaded inverted hexagons, antibodies.
Neutralizing Antiviral Antibodies Reduce
Hematogenic Viral Spread but Not Antiviral
Cytotoxic T Cell Induction and Subsequent
Immunopathology
To the Editor—In their article on treatment of respiratory syn-
cytial virus (RSV) bronchiolitis and pneumonia in a cotton rat
model, Prince et al. [1] observe that parenteral treatment with
a monoclonal antibody (MAb) directed against the viral F pro-
tein resulted in the clearance of infectious virus but had only
a small effect on the pulmonary pathology. Earlier studies dem-
onstrated that immunoglobulin therapy for RSV infection, al-
though safe, resulted in no clinically beneficial outcome [2, 3].
The article by Prince et al. is further evidence that the virus-
host relationship is complex and is influenced by many factors,
such as the virus, viral kinetics, viral genotypes, and host factors
(e.g., cytokine responses, type and kinetics of cytotoxic and
CD4 T cell responses, and major histocompatibility complex
presentation) [4, 5].
Studies with the noncytopathic lymphocytic choriomeningitis
virus (LCMV) in mice produced several interesting findings that
could explain, in part, phenomena observed for RSV infection,
in particular, data reported by Prince et al. [1]. Immunization
with subunit vaccines may change the relative balance between
virus spread and the immune response. This was observed in
a study of the noncytopathic LCMV, where immunization with
a recombinant vaccinia virus expressing the LCMV glycopro-
tein, nucleoprotein, or the corresponding peptide protected mice
from LCMV disease by induction of a protective cytotoxic T
cell (CTL) response; however, identical immunization aggra-
vated disease after infection with certain LCMV isolates via
enhancement of T cell–mediated immunopathology [6, 7]. Sim-
ilar influences on the immune balance may explain why a for-
malin-inactivated RSV vaccine not only failed to protect vac-
cine recipients in the late 1960s but also led to enhanced illness
after natural exposure to the virus [8].
Of importance, the findings by Prince et al. [1] are strikingly
similar to those found earlier for LCMV. Neutralizing anti-
LCMV antibodies protected against hematogenic virus spread
and prevented infection of the spleen or lymphoid cells but had
little effect on viral infection of cells and spread between cells
in solid peripheral tissues, such as the footpad or meninges (i.e.,
the initial site of infection) [9]. Neutralizing anti-LCMV anti-
bodies regulated the balance between virus spread relative to
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the kinetics of the disease-causing CD8 T cell responses and
thereby changed the outcome of immunopathologic disease.
When mice were intracerebrally challenged with a low dose
of the slowly replicating LCMV Armstrong isolate, virus spread
to the spleen and induced CTL responses, which then were
directed against infected choriomeningeal cells, causing lethal
immunopathology (figure 1A). Preexisting neutralizing anti-
bodies efficiently prevented the hematogenic spread of this iso-
late and reduced the induction of CTL virtually completely and
hence prevented immunopathology (figure 1B) [9]. After intra-
cerebral or footpad infection with the faster replicating isolate
LCMV-WE, preexisting antiviral antibodies again reduced the
hematogenic spread and reduced CTL induction. However,
neutralizing antibodies could not sufficiently control viral rep-
lication, and thereby CTL responses, to attenuate lethal cho-
riomeningitis or an immunopathologic footpad swelling (i.e.,
disease at the sites of primary infection; figure 1C) [9, 10]. In
accordance with these findings, the results of Prince et al. [1]
could be explained as follows: after infection with RSV, treat-
ment with MAbs directed against viral F protein resulted in a
subtotal clearance of infectious virus. Remaining virus, despite
the dramatic viral clearance, still was replicating sufficiently in
the periphery to induce efficient (cellular) immune responses
and to cause pulmonary disease (figure 1C).
The LCMV model may also explain why treatment with
parenteral triamcinolone acetonide dramatically reduced the
pathologic lesions of viral bronchiolitis and pneumonia but
resulted in delayed clearance of the virus. Of interest, after
infection with the slowly replicating LCMV Armstrong isolate,
treatment with neutralizing antiviral antibodies not only dras-
tically lowered primary CTL responses and immunopathologic
disease but also delayed viral elimination (figure 1B); LCMV
still was measurable at high titers in brains (i.e., at the site of
infection). After infection with RSV, treatment with cortico-
steroids most likely reduced cellular immune responses, thereby
preventing immunopathology and also clearance of the virus.
In our view, the LCMV model may help to elucidate the
course of experimental RSV infection after parenteral treatment
with MAbs. The data of Prince et al. [1] and of our study
demonstrate that neutralizing antiviral antibodies and/or im-
munosuppression may drastically alter the kinetics of virus
present in initially infected peripheral organs versus secondary
lymphoid tissues yet may alter immune responses and result in
modulated immunopathology. Thus, optimal vaccines and
treatments should be efficient, both locally in tissues via acti-
vated T cells and systemically via soluble factors, including
protective antibodies.
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Reply
To the Editor—We are pleased that Battegay et al. [1] support
the basic finding of our paper [2], that therapy for certain viral
diseases should target both the elimination of the infectious
agent and the modulation of the host inflammatory response.
Although we believe that the model of lymphocytic chorio-
meningitis virus (LCMV) in mice may provide valuable clues
to the pathogenesis, prevention, and treatment of other infec-
tious diseases, we think that it is important to comment on
several of the observations by Battegay et al. that may not be
direct parallels of the work we described.
First, our study used a single approach to respiratory syn-
cytial virus (RSV) disease, passive immunotherapy using a
monoclonal antibody. Thus, the observations of Battegay et al.
[1] about active immunization, although of potential value in
understanding vaccine-enhanced RSV disease, are of less rele-
vance to the work we described. Second, their description of
antibody studies in LCMV disease deals with passive immu-
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noprophylaxis of a systemic viral disease, whereas our study
examined only passive immunotherapy for a self-limiting mu-
cosal infection. Third, although their studies show that pro-
phylactic antibody to LCMV may, under certain circumstances,
enhance the disease process, our studies and those of several
clinical trials showed no evidence that antibody therapy for
RSV accentuated disease. Fourth, their hypothesis that our
results could be explained by subtotal clearance of virus, with
remaining virus then inducing the pathologic inflammatory re-
sponse, does not take into account the fact that immunotherapy
was not initiated until the peak of viral replication, by which
time host inflammatory changes were already well under way.
Nonetheless, we are grateful for their supportive comments
and are confident that they are reflective of a growing awareness
of the role of host inflammation in infectious disease patho-
genesis, with the attendant implications for therapy.
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Timing of Human Immunodeficiency Virus Type 1
and Human Herpesvirus 8 Infections and Length
of the Kaposi’s Sarcoma–Free Period
in Coinfected Persons
To the Editor—In 1998, we reported that human immunodefi-
ciency virus type 1 (HIV-1)–infected homosexual men have the
highest risk of developing Kaposi’s sarcoma (KS) if they acquire
human herpesvirus 8 (HHV-8) after HIV infection [1]. This ob-
servation has been confirmed recently by Jacobson et al. [2], who
also found that the duration of HIV-1 infection before HHV-8
acquisition influences the risk for KS. Therefore, we [1] and Ja-
cobson et al. [2] suggested that immunodeficiency at the time of
primary HHV-8 infection may shorten the KS-free period.
In a subsequent correspondence, Rezza [3] suggested that
this is not necessarily the case, since most cases of transplant-
associated KS in an HHV-8–endemic country occurred in pa-
tients who had acquired HHV-8 before transplantation [4].
Rezza infers from these data that factors like HIV-1 Tat and/
or inflammatory cytokines, rather than immunosuppression,
might be responsible for the increased incidence of KS in HIV-
1 and HHV-8 coinfected persons.
Jacobson and Jenkins [5] responded to the report by Rezza
[3] by suggesting that KS in HIV-1–negative transplant recipi-
ents cannot be formally compared with KS in HIV-1–positive
individuals in regard to the impact of immunosuppression on
the rate of progression of HHV-8 infection to KS. We agree
with the comments of Jacobson and Jenkins and wish to point
out that, in our original report [1], CD4 cell count, not HIV-
1 virus load, was an independent risk factor for KS. In our
view, it is therefore more likely that HIV-related immunodefi-
ciency, rather than steady-state levels of HIV in blood, and, by
inference, levels of HIV-1 Tat or inflammatory cytokines in-
crease the risk for KS.
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No Increase in Liver Decompensation Risk
with Atypical Hepatitis C Virus Antibody Pattern
To the Editor—Goedert et al. [1] found a surprising correlation
between high anti–hepatitis C virus (HCV) c100 and low anti–c22
reactivity in RIBA and liver decompensation during an average
of 3 years of follow-up of patients with hemophilia coinfected
with HCV and human immunodeficiency virus (HIV). They out-
lined the need of corroboration of such findings in both HCV-
HIV–coinfected subjects and persons infected only with HCV.
We retrospectively examined the results of anti-HCV antibody
determination in Western blot testing (Murex Diagnostics) of
241 HCV-infected (HCV-RNA positive) patients (6 HIV-coin-
fected [none with hemophilia]) followed up in our outpatient
clinic and correlated these findings with eventual decompensation
during a mean follow-up of 3 years.
Of the 241 patients, only 5 (1 of whom was coinfected with
HIV) had, when first tested, high levels of anti-NS4 antibodies
(, Western blot) and low levels of anti-core antibodies
(, Western blot). None of the 5 had any episode of decom-
pensation during follow-up, whereas 5 other patients (1 HIV-
positive patient) developed ascites and/or hepatic encephalo-
pathy. Because the c100 and c22 peptides used in RIBA overlap
NS4 and core, respectively, in Western blot, our results, al-
though confirming that low anti-core reactivity in the face of
high anti-NS4 levels is atypical, do not show any correlation
of this pattern with impending liver decompensation. Although
our findings are in a nonhemophilic, largely non-HIV–infected
cohort, they show that high anti-NS4 (c100) and low anti-core
(c22) antibody levels cannot be regarded as potential surrogate
markers of progressive liver disease in all HCV-infected persons.
Maria Serena Longhi, Francesca Cainelli,
Ercole Concia, and Sandro Vento
Department of Infectious Diseases, University of Verona, Verona, Italy
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A Pathologist’s View of Organisms and Human
Atherosclerosis
To the Editor—Several different organisms have been associated
with ischemic heart disease. Reports of remnants or viable or-
ganisms in human atherosclerotic lesions have led to the sug-
gestion that the lesions could, in part, be due to various infec-
tious agents, either separately or in combination.
The antibody status of some organisms has been studied in
patients with ischemic heart disease and has been compared with
findings in persons free of symptoms. These studies examined
antibodies to Chlamydia pneumoniae, cytomegalovirus, Helico-
bacter pylori, dental bacteria, and hepatitis A virus [1]. The ra-
tionale for selecting the specific antibodies for study in this group
of patients is not clear. If one were to study the antibody status
of every pathogen in humans, it would seem reasonable to expect
that a certain percentage of organisms would be more common
in patients with ischemic heart disease and that a certain per-
centage would be less common in such a group.
What is the status of bacterial infections, viruses, and fungal
and parasitic infections in patients with ischemic heart disease?
Can we conclude that organisms that are more frequent in
patients with cardiac ischemia have a role in ischemia and that
those that are decreased somehow protect against ischemia of
the heart muscle? The association with atherosclerosis of the
arteries in this group is tenuous, in that ischemia of the heart
cannot be equated with and is not an indication of the severity
of atherosclerosis [2].
Atherosclerosis is an arterial disease mainly of the aorta and
larger arteries. The coronary arteries are but a small part of
atherosclerosis and hardly indicate the extent of the lesion. It
is not correct to assume that the clinical symptom of ischemia
of the cardiac muscle is solely due to atherosclerosis or that it
is an indication of the extent and severity of atherosclerotic
disease in the arterial vasculature [2].
Another group of studies has been concerned with the mo-
lecular detection of microorganisms in atherosclerotic lesions.
In the 1980s, various herpesvirus remnants were found in ath-
erosclerotic lesions in the aorta and normal aortic tissue. Re-
cently, it was reported that DNA of H. pylori [3] and certain
dental bacteria [4] are present in atherosclerotic lesions. The
finding of polymerase chain reaction–positive material has not
always been consistent, and there have been calls to standardize
these methods. It seems improbable that pathologists examining
these lesions could overlook such large organisms. The impli-
cations of finding DNA remnants in these lesions have not been
fully addressed. Whether the DNA is in the intima (where ath-
erosclerosis occurs) or in the media or adventitia is not clear.
Is the DNA present in blood? Blood is invariably present in
the specimen that is examined (arteries not only are in contact
with blood but are supplied by vasovasorum that contain
blood). From a practical point of view, atherosclerotic arterial
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lesions with features akin to those of herpesviruses, hepatitis
A virus, H. pylori, or dental bacteria are not seen. Pathologi-
cally, it is difficult to accept that a lesion with such specific
constant features can be caused by a variety of different viruses
and bacteria.
C. pneumoniae is associated with atherosclerosis in a different
way. The human atherosclerotic lesion is considered to be lipid
related. Initial electron microscopy studies in the 1960s ex-
amined the nature of lipid in human atherosclerotic lesions and
revealed that most lipid structures were in different forms [5].
Small double membrane–bound structures were called vesicles,
others were called small lipid droplets, some were called dense
bodies, and others were called “unknown structures.” Larger
forms were called dense reticular membrane–bound lipid. Vac-
uoles also were described. These contained dense lipid bodies.
At more or less the same time, electron microscopy studies of
cultured Chlamydia organisms illustrated structures that were
identical to those described and illustrated in the studies of
human atherosclerosis [6]. These consisted of smaller elemen-
tary forms and larger reticulate organisms growing in vacuoles.
The pathologists were unaware of the features of Chlamydia
organisms, and the chlamydiologists were unaware of the fea-
tures of lipid structures in human atherosclerotic lesions. In the
1990s, the question of identification of these structures was
addressed [7–9]. The current evidence, which is accumulating,
suggests that these structures may well be C. pneumoniae. The
implications are that previously overlooked or misinterpreted
major inherent components may consist largely of chlamydiae
and not fat, as accepted. From a pathologic point of view, not
only are Chlamydia-like structures present in human athero-
sclerotic lesions, but a reassessment of the lesion in light of the
new findings shows that most of these lesions have specific
constant pathologic features, which are consistent with those
of a chronic chlamydial granuloma or chlamydioma of the
arteries [10].
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National Centre for Occupational Health, Johannesburg, South Africa
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